Format

Send to

Choose Destination
See comment in PubMed Commons below
Gynecol Oncol. 2013 Jun;129(3):613-9. doi: 10.1016/j.ygyno.2013.02.011. Epub 2013 Feb 17.

Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies.

Author information

1
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Abstract

OBJECTIVE:

The aim of this study was to evaluate the prognostic significance of cyclooxygenase-2 (COX-2) on survival in patients with ovarian cancer by using a meta-analysis of observational studies.

METHODS:

We searched Pubmed and Embase to retrieve observational studies evaluating the association between COX-2 status and survival in patients with ovarian cancer. Hazards ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were pooled across studies using a random-effects model.

RESULTS:

A total of 17 studies were included in this meta-analysis to estimate the association between COX-2 and overall survival (OS), disease-free survival (DFS), response to chemotherapy (RC), and other clinical parameters. In a random-effects meta-analysis of 15 studies, higher COX-2 expression significantly predicted poor OS (death HR, 1.34; 95% CI, 1.05-1.71; I(2)=56.5%). A more prominent association was found between COX-2 expression and poor OS when studies with adjustment for age, stage, and histology were included (death HR, 1.65; 95% CI, 1.25-2.17; I(2)=0%). However, higher COX-2 expression was not significantly associated with poor DFS (recurrence HR, 1.36; 95% CI, 0.79-2.33; I(2)=53.6%) and RC (OR, 1.89; 95% CI, 0.85-4.21; I(2)=17.6%). There was a marginally significant association between COX-2 positivity and several clinical parameters such as age, stage, and histology. The pooled ORs of higher COX-2 expression were 1.75 (95% CI, 1.01-3.04) for advanced stages, 1.34 (95% CI, 0.97-1.85) for old age, and 1.42 (95% CI, 0.98-2.05) for serous cancer in histologic type, respectively.

CONCLUSIONS:

The present meta-analysis suggests that higher COX-2 expression may be an independent risk factor for poor OS in patients with ovarian cancer.

PMID:
23422504
DOI:
10.1016/j.ygyno.2013.02.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center